Does treatment with daraxonrasib following chemotherapy improve survival
Review a document
The project
This project is a Phase 3, global, randomized, open-label, 2-arm study designed to evaluate whether treatment with daraxonrasib following completion of neo-/adjuvant chemotherapy improves disease survival. Patients that had prior therapy will receive the study drug, to compare to patients that had the tumour surgically removed and didn’t receive this study drug, to see if the survival chances are increasing.
What are you going to do?
The Screening Period will occur within 28 days after signing the main study Informed Consent Form (ICF). During this Period, patient eligibility will be determined. For patients randomized to study treatment with daraxonrasib (Arm A), the Treatment Period will extend from Day 1 until recurrence of disease, intolerance, treatment discontinuation criterion is met, or treatment is completed, whichever occurs first. The maximum treatment duration is 2 years. Patients will visit the clinic every 4 weeks during the Treatment Period for safety and tolerability assessments and return for Follow up visits.
Why is this research important?
If the study medication will work as intended in patients with pancreatic cancer, the patient population diagnosed early enough will have a longer period of progression free survival and maybe even overall survival.
How to get involved
The team are asking for you help to review the documents associated with this trial to ensure it is easy to understand for patients that are going to be getting involved in the trial.
No scientific background or prior experience is needed to take part in this opportunity.
Next steps
If you are interested in reviewing the document, please email The Research Team (research@pancreaticcancer.org.uk) quoting the involvement reference ‘Document review’ we will then send you the document to review which needs to be returned to us by Sunday 9th November 2025.
